Synaptogenix applauds dea proposal to reclassify cannabis and shares expected benefits to cannasoul for cannabinoid-based drug discovery

Proposed schedule iii drug classification expected to de-risk cannasoul's cannabis research and potential regulatory pathways new york , may 7, 2024 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the u.s. drug enforcement agency (the "dea") to recommend reclassifying cannabis as a schedule iii drug, and announces potential benefits of the rescheduling to its partner cannasoul analytics ("cannasoul"), founded by the technion-israel institute of technology, in its discovery of cannabis-based therapeutics. as reported in the press on april 30, 2024, the dea will move to reclassify cannabis from a schedule i drug to a schedule iii under the controlled substance act on recommendation by the u.s. department of health and human services.
SNPX Ratings Summary
SNPX Quant Ranking